放疗期间超声Delta影像组学预测头颈鳞癌复发
随访中位38个月,17例复发;第1周支持向量机分类器准确率80%、AUC 0.75,第4周提升至82%和0.81。结论认为定量超声Delta影像组学能以合理准确度预测HNSCC复发风险。
要点
- 放疗第1周定量超声Delta影像组学预测复发准确率80%、AUC 0.75。
- 放疗第4周模型性能提升至准确率82%、AUC 0.81。
核心结论
- 定量超声Delta影像组学可在头颈鳞癌中以合理准确度预测较高的复发风险。
研究设计与样本
- 在放疗前及放疗第1周、第4周扫描颈部索引淋巴结采集射频数据,提取31个频谱及相关纹理特征并计算Delta特征。
- 按临床结局分为复发组与未复发组,采用三种机器学习分类器建模,特征经前向序列选择并用留一交叉验证评估。
主要发现
- 全组随访中位38个月(范围7–64个月),复发17例。
- 放疗第1周支持向量机分类器性能最佳,准确率80%、AUC 0.75。
- 放疗第4周准确率与AUC分别提升至82%和0.81。
临床怎么用
- 可在放疗第1周及第4周利用临床超声设备采集颈部索引淋巴结定量超声数据,辅助识别复发高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study investigated the use of quantitative ultrasound (QUS) obtained during radical radiotherapy (RT) as a radiomics biomarker for predicting recurrence in patients with node-positive head-neck squamous cell carcinoma (HNSCC). METHODS: Fifty-one patients with HNSCC were treated with RT (70 Gy/33 fractions) (±concurrent chemotherapy) were included. QUS Data acquisition involved scanning an index neck node with a clinical ultrasound device. Radiofrequency data were collected before starting RT, and after weeks 1, and 4. From this data, 31 spectral and related-texture features were determined for each time and delta (difference) features were computed. Patients were categorized into two groups based on clinical outcomes (recurrence or non-recurrence). Three machine learning classifiers were used for the development of a radiomics model. Features were selected using a forward sequential selection method and validated using leave-one-out cross-validation. RESULTS: The median follow up for the entire group was 38 months (range 7-64 months). The disease sites involved neck masses in patients with oropharynx (39), larynx (5), carcinoma unknown primary (5), and hypopharynx carcinoma (2). Concurrent chemotherapy and cetuximab were used in 41 and 1 patient(s), respectively. Recurrence was seen in 17 patients. At week 1 of RT, the support vector machine classifier resulted in the best performance, with accuracy and area under the curve (AUC) of 80% and 0.75, respectively. The accuracy and AUC improved to 82% and 0.81, respectively, at week 4 of treatment. CONCLUSION: QUS Delta-radiomics can predict higher risk of recurrence with reasonable accuracy in HNSCC.Clinical trial registration: clinicaltrials.gov.in identifier NCT03908684.
引用
- Fatima K, Dasgupta A, DiCenzo D, et al. Ultrasound delta-radiomics during radiotherapy to predict recurrence in patients with head and neck squamous cell carcinoma. Clin Transl Radiat Oncol. 2021. PMID: 33778174. doi:10.1016/j.ctro.2021.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。